GlaxoSmithKline Business Case Analysis: Strategy & Finance
This paper presents a comprehensive business case analysis of GlaxoSmithKline (GSK), one of the world's largest pharmaceutical companies. The analysis addresses three core case issues: consumers purchasing drugs from abroad at lower prices, product development concerns related to drug side effects, and GSK's strategy for expanding access to medicines in developing countries. The paper examines GSK's current performance and strategic posture, corporate governance structure, external and internal environments through a SWOT framework, Porter's Five Forces, key financial ratios, and human resource practices. It concludes with strategic alternatives and a recommended pricing strategy, alongside an implementation and evaluation plan.
- Introduction and Case Issues: GSK's three core strategic problems introduced
- Corporate Governance and Leadership: Board composition and top management roles
- External Environment: Opportunities and Threats: PESTLE factors and Porter's Five Forces analysis
- Internal Environment: Strengths and Weaknesses: Corporate structure, culture, finance, R&D, and HR
- Analysis of Strategic Factors (SWOT): Consolidated SWOT and mission alignment review
- Strategic Alternatives and Recommended Strategy: Pricing strategy recommended to address abroad purchases
- Implementation, Evaluation, and Control: Dual-channel rollout and government oversight plan
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper applies a structured, multi-framework analytical approach — combining SWOT analysis, Porter's Five Forces, financial ratio analysis, and strategic management frameworks — to a single company, demonstrating thorough coverage of a business case.
- Each case issue (CI#1, CI#2, CI#3) is consistently flagged throughout every section, creating a clear thread of argument that ties observations back to the central problems.
- The financial analysis section moves beyond surface description by comparing GSK's ratios to industry averages, providing meaningful interpretive context for each metric.
Key academic technique demonstrated
The paper demonstrates integrated strategic analysis: rather than treating each framework in isolation, it uses SWOT, Porter's Five Forces, and financial ratios as complementary lenses. For example, external threats identified in the environmental scan directly inform the recommended pricing strategy, showing how analytical tools can be layered to produce actionable business recommendations.
Structure breakdown
The paper follows a classic business case report structure: it opens with a current situation assessment (performance and strategic posture), moves through corporate governance, then proceeds outward-to-inward with the external environment before the internal environment, synthesizes both in a SWOT analysis, and closes with strategic alternatives, a recommended strategy, and an evaluation plan. This logical progression from diagnosis to prescription is a hallmark of graduate-level business case writing.
Introduction and Case Issues
Case Issue 1: Abroad Purchase. GlaxoSmithKline faces lower sales revenues within the United States as consumers prefer to purchase their drugs from abroad at lower prices.
Case Issue 2: Product Development. GlaxoSmithKline has been criticized for the side effects of some of its medicines and therefore needs to invest more in product research and development.
Case Issue 3: International Expansion. Although GlaxoSmithKline already operates in 150 countries around the globe, the company seeks to penetrate the markets of developing and less-developed countries in order to increase patients' access to medicines.
Current Performance
GlaxoSmithKline is the world's most renowned pharmaceutical company, with annually increasing turnovers, investments, and profits. It plays a significant role in both national and international healthcare industries.
GlaxoSmithKline's profitability for 2006 is measured with the aid of five profitability ratios: gross margin, operating margin, pre-tax margin, net profit margin, and effective tax rate.
The profit after taxes for 2006 was £5,498 million, 14% higher than the profit recorded for 2005 (GSK 2006 Annual Report). The 7% turnover growth in fiscal year 2006 compared to 2005 is explained by increased sales of the company's main products. Specifically:
The market share by value in the anti-asthma and COPD class registered 29% in European countries and 33% in the United States. The market share for 2006 within Europe registered a 2% increase compared to fiscal year 2005, but within the United States the market share was stagnant. The lack of growth in the U.S. market is due to lower prescriptions generated by "a label change in early 2006 that restricted GSK's ability to promote the product, offset by favourable pricing changes" (GSK Website, 2007).
During fiscal year 2006, GlaxoSmithKline recorded a 29.66% return on investment, compared to an industry average of 13.56% (Reuters, 2007).
Strategic Posture
Mission. GSK's mission is clearly stated on its website, banners, posters, and annual reports, and is visible throughout its campaigns and actions. The company's mission is to improve the quality of human life by enabling people to do more, feel better, and live longer (GSK Website, 2007). Directly connected to this mission is the company's spirit: GSK describes itself as a group of enthusiastic entrepreneurs dedicated to innovation, valuing integrity, high performance, and fair employee treatment, with the ultimate goal of becoming a successful world-class global leader (GSK 2006 Annual Report).
Objectives. The company's objectives are not explicitly stated, but are implied through actions, performances, and statistics. From these sources, GSK's objectives can be structured as follows:
Increase both national and international market share (CI#3); sustain growth in Europe and promote growth in the U.S.; increase turnover, sales revenues, and profits; value employees and increase their commitment to the company; invest in Research and Development in order to discover new medicines and improve existing ones (CI#2); and produce the best and most competitive products.
Strategies (GSK 2006 Annual Report):
1) Optimizing the performance of key products (CI#2). This strategy is implemented to increase sales of the corporation's major products. Activities developed toward this goal include excelling as an international sales force; excelling in marketing pharmaceutical and consumer healthcare products and services; promoting and maintaining the highest professional and ethical standards; and balancing the cost-benefit relationship.
2) Delivering the product pipeline for patients. This strategy involves developing a system to support and manage GSK's product pipeline throughout each product's complete life cycle. It is primarily based on innovations made by the Research and Development Department and aims to satisfy the unmet needs of customers.
3) Being the best place for the best people to do their best work. This strategy is based on the desire to register the highest organizational performance and is implemented through four actions: recruitment and training of the best-qualified personnel; promotion of a culture based on adequate rewards and motivating incentives; implementation of effective communication and employee involvement in organizational goals; and hiring qualified, diverse, and healthy personnel.
4) Improving access to medicines (CI#3). This strategy was developed to give more individuals the opportunity to purchase medical products and services. GlaxoSmithKline takes pride in its efforts to improve access to drugs by penetrating neglected markets and developing medicines to treat neglected diseases.
Policies. GSK has developed its policies in full accordance with social, economic, political, and legal contexts, using them as guiding elements in achieving its mission. The most prominent policies cover the company's code of conduct, clinical trials, sales and marketing ethics, informed consent, animals in research, genetic research, drug safety, and the reporting of safety data (GSK Website, 2007).
Create your account
Always verify citation format against your institution’s current style guide requirements.